Home > Boards > US Listed > Biotechs > RedHill Biopharma Ltd. (RDHL)

I’ve been adding some over the past few

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
noretreat Member Profile
 
Followed By 121
Posts 11,808
Boards Moderated 0
Alias Born 01/06/10
160x600 placeholder
ObvioHealth and RedHill Biopharma Launch First in Kind Remote COVID-19 Therapy Trial Incorporating Highest Level of At-home P... PR Newswire (US) - 3/2/2021 9:06:00 AM
NIO, C3.ai leads the premarket losers' pack Seeking Alpha - 3/2/2021 8:55:29 AM
RedHill increases bought deal offering to $35M Seeking Alpha - 3/2/2021 8:42:26 AM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 3/2/2021 8:26:51 AM
RedHill Biopharma Increases Previously Announced Bought Deal to $35 Million of American Depositary Shares PR Newswire (US) - 3/2/2021 8:23:00 AM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 3/1/2021 5:09:07 PM
RedHill enters $10M bought deal offering Seeking Alpha - 3/1/2021 5:00:57 PM
RedHill Biopharma Announces $10 Million Bought Deal Offering of American Depositary Shares PR Newswire (US) - 3/1/2021 4:53:00 PM
RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S. PR Newswire (US) - 2/23/2021 7:13:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/23/2021 7:11:44 AM
RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S. PR Newswire (US) - 2/23/2021 7:03:00 AM
RedHill Bio inks manufacturing deal for Movantik and RHB-204 Seeking Alpha - 2/18/2021 7:58:04 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/18/2021 7:00:47 AM
RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204 PR Newswire (US) - 2/18/2021 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/17/2021 7:09:44 AM
RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107 PR Newswire (US) - 2/17/2021 7:00:00 AM
RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107 PR Newswire (US) - 2/17/2021 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/9/2021 7:00:42 AM
RedHill Biopharma to Present at SVB Leerink Global Healthcare and BIO CEO & Investor Conferences PR Newswire (US) - 2/9/2021 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/2/2021 8:01:02 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/29/2021 7:00:57 AM
RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib PR Newswire (US) - 1/29/2021 7:00:00 AM
RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals PR Newswire (US) - 1/28/2021 8:02:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/28/2021 7:31:37 AM
RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals PR Newswire (US) - 1/28/2021 7:27:00 AM
noretreat   Thursday, 11/28/19 06:26:48 PM
Re: Amatuer17 post# 1797
Post # of 2851 
I’ve been adding some over the past few weeks. I expect volatility as well.

You have to like the fact that they have continued to do what they planned to do.

No Retreat ... No Surrender
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences